| **Characteristic** | **1** N = 401 | **2** N = 700 | **p-value***1* |
| --- | --- | --- | --- |
| age, Median (IQR) | 32 (26 – 41) | 44 (30 – 57) | <0.001 |
| sex, n (%) |  |  | <0.001 |
| Female | 15 (3.7) | 459 (66) |  |
| Male | 386 (96) | 241 (34) |  |
| height, Median (IQR) | 180 (177 – 185) | 166 (161 – 173) | <0.001 |
| weight, Median (IQR) | 84 (75 – 98) | 72 (61 – 84) | <0.001 |
| bmi, Median (IQR) | 25.6 (23.0 – 29.2) | 25.5 (22.6 – 29.3) | 0.75 |
| age\_at\_diagnosis, Median (IQR) | 27 (22 – 37) | 30 (21 – 48) | <0.001 |
| montreal\_upper\_gi, n (%) |  |  | 0.57 |
| 0 | 389 (97) | 683 (98) |  |
| 1 | 12 (3.0) | 17 (2.4) |  |
| montreal\_perianal, n (%) |  |  | 0.28 |
| 0 | 376 (94) | 667 (95) |  |
| 1 | 25 (6.2) | 33 (4.7) |  |
| has\_active\_symptoms, n (%) |  |  | 0.004 |
| 0 | 150 (37) | 203 (29) |  |
| 1 | 251 (63) | 497 (71) |  |
| albumin, Median (IQR) | 39.0 (37.0 – 42.0) | 38.0 (35.0 – 40.0) | <0.001 |
| crp, Median (IQR) | 3 (1 – 7) | 3 (1 – 6) | >0.99 |
| haemoglobin, Median (IQR) | 145 (136 – 152) | 133 (125 – 140) | <0.001 |
| red\_cell\_count, Median (IQR) | 4.90 (4.57 – 5.11) | 4.49 (4.15 – 4.76) | <0.001 |
| white\_cell\_count, Median (IQR) | 6.90 (5.60 – 8.30) | 7.30 (5.90 – 9.10) | <0.001 |
| neutrophils, Median (IQR) | 4.30 (3.20 – 5.60) | 4.65 (3.50 – 6.24) | <0.001 |
| lymphocytes, Median (IQR) | 1.60 (1.22 – 2.00) | 1.65 (1.29 – 2.15) | 0.005 |
| monocytes, Median (IQR) | 0.56 (0.45 – 0.74) | 0.55 (0.40 – 0.69) | 0.002 |
| eosinophils, Median (IQR) | 0.13 (0.07 – 0.24) | 0.12 (0.05 – 0.20) | <0.001 |
| basophils, Median (IQR) | 0.03 (0.02 – 0.06) | 0.03 (0.01 – 0.05) | 0.14 |
| platelets, Median (IQR) | 287 (244 – 333) | 313 (266 – 364) | <0.001 |
| urea, Median (IQR) | 4.40 (3.70 – 5.10) | 4.40 (3.60 – 5.10) | 0.10 |
| creatinine, Median (IQR) | 80 (72 – 88) | 67 (58 – 74) | <0.001 |
| sodium, Median (IQR) | 140.00 (139.00 – 141.00) | 139.00 (138.00 – 140.00) | <0.001 |
| potassium, Median (IQR) | 4.30 (4.10 – 4.50) | 4.30 (4.10 – 4.50) | 0.21 |
| calprotectin, Median (IQR) | 295 (155 – 539) | 295 (138 – 399) | 0.12 |
| sampling\_steroids, n (%) |  |  | <0.001 |
| 0 | 329 (82) | 513 (73) |  |
| 1 | 72 (18) | 187 (27) |  |
| sampling\_abx, n (%) |  |  | 0.66 |
| 0 | 392 (98) | 687 (98) |  |
| 1 | 9 (2.2) | 13 (1.9) |  |
| sampling\_asa, n (%) |  |  | 0.008 |
| 0 | 309 (77) | 487 (70) |  |
| 1 | 92 (23) | 213 (30) |  |
| sampling\_aza, n (%) |  |  | 0.52 |
| 0 | 338 (84) | 600 (86) |  |
| 1 | 63 (16) | 100 (14) |  |
| sampling\_mp, n (%) |  |  | 0.24 |
| 0 | 389 (97) | 669 (96) |  |
| 1 | 12 (3.0) | 31 (4.4) |  |
| sampling\_ifx, n (%) |  |  | 0.31 |
| 0 | 332 (83) | 562 (80) |  |
| 1 | 69 (17) | 138 (20) |  |
| sampling\_ada, n (%) |  |  | 0.44 |
| 0 | 323 (81) | 577 (82) |  |
| 1 | 78 (19) | 123 (18) |  |
| sampling\_vedo, n (%) |  |  | <0.001 |
| 0 | 380 (95) | 606 (87) |  |
| 1 | 21 (5.2) | 94 (13) |  |
| sampling\_uste, n (%) |  |  | 0.56 |
| 0 | 357 (89) | 631 (90) |  |
| 1 | 44 (11) | 69 (9.9) |  |
| sampling\_tofa, n (%) |  |  | 0.54 |
| 0 | 394 (98) | 691 (99) |  |
| 1 | 7 (1.7) | 9 (1.3) |  |
| sampling\_mtx, n (%) |  |  | 0.74 |
| 0 | 393 (98) | 688 (98) |  |
| 1 | 8 (2.0) | 12 (1.7) |  |
| sampling\_ciclosporin, n (%) |  |  | >0.99 |
| 0 | 400 (100) | 698 (100) |  |
| 1 | 1 (0.2) | 2 (0.3) |  |
| sampling\_filgo, n (%) |  |  | 0.11 |
| 0 | 389 (97) | 689 (98) |  |
| 1 | 12 (3.0) | 11 (1.6) |  |
| sampling\_upa, n (%) |  |  | <0.001 |
| 0 | 374 (93) | 686 (98) |  |
| 1 | 27 (6.7) | 14 (2.0) |  |
| sampling\_risa, n (%) |  |  | 0.63 |
| 0 | 399 (100) | 698 (100) |  |
| 1 | 2 (0.5) | 2 (0.3) |  |
| disease\_duration\_weeks, Median (IQR) | 276 (78 – 505) | 274 (55 – 919) | 0.025 |
| diagnosis\_year, Median (IQR) | 2,017 (2,012 – 2,021) | 2,018 (2,005 – 2,022) | 0.011 |
| fatigue\_outcome, n (%) | 140 (35) | 368 (53) | <0.001 |
| study\_group, n (%) |  |  | 0.022 |
| CD | 254 (64) | 385 (55) |  |
| UC | 141 (35) | 301 (43) |  |
| IBDU | 3 (0.8) | 9 (1.3) |  |
| Unknown | 3 | 5 |  |
| montreal\_cd\_location, n (%) |  |  | <0.001 |
| L1 | 17 (6.8) | 77 (21) |  |
| L2 | 113 (45) | 165 (44) |  |
| L3 | 119 (48) | 130 (35) |  |
| Unknown | 152 | 328 |  |
| montreal\_cd\_behaviour, n (%) |  |  | 0.20 |
| B1 | 169 (68) | 241 (66) |  |
| B2 | 40 (16) | 79 (22) |  |
| B3 | 39 (16) | 47 (13) |  |
| Unknown | 153 | 333 |  |
| montreal\_uc\_extent, n (%) |  |  | 0.033 |
| E1 | 3 (2.9) | 14 (5.1) |  |
| E2 | 47 (45) | 156 (57) |  |
| E3 | 55 (52) | 103 (38) |  |
| Unknown | 296 | 427 |  |
| montreal\_uc\_severity, n (%) |  |  | <0.001 |
| S0 | 37 (32) | 23 (10) |  |
| S1 | 20 (17) | 49 (22) |  |
| S2 | 46 (39) | 109 (49) |  |
| S3 | 14 (12) | 40 (18) |  |
| Unknown | 284 | 479 |  |
| smoking\_status, n (%) |  |  | 0.016 |
| Non-smoker | 291 (75) | 471 (69) |  |
| Ex-smoker | 62 (16) | 160 (23) |  |
| Smoker | 36 (9.3) | 55 (8.0) |  |
| Unknown | 12 | 14 |  |
| season, n (%) |  |  | 0.32 |
| Spring | 84 (22) | 138 (20) |  |
| Summer | 111 (29) | 206 (30) |  |
| Autumn | 98 (25) | 201 (29) |  |
| Winter | 95 (24) | 142 (21) |  |
| Unknown | 13 | 13 |  |
| *1*Wilcoxon rank sum test; Pearson's Chi-squared test; Fisher's exact test | | | |